探花精选

Rolf Lewensohn

Rolf Lewensohn

Professor | Professor, Senior | Docent
Visiting address: BioClinicum v盲n 6, Visionsgatan 4, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Ekman Lewensohn, 171 77 Stockholm
Part of:

About me

  • Professor of Oncology, Karolinska Institute
  • Senior Consultant, Oncology Clinic, Karolinska Hospital.

    - Born 1949
  • leader of a Research Group with some 20 members at the Karolinska Institute Department of Oncology-Pathology.
    - Programme Director, Swedish Radiation Emergency Medicine Centre (KcRN), a radiation emergency function of the Swedish Board of Health and Welfare.
    - Member of the Scientific Boards of several Swedish funding bodies.
    - Author of more than 110 research papers on cancer.

Research

  • Rolf Lewensohn has a scientific background in DNA repair apoptotic signalling in cancer as related to cancer therapy. His research focuses on the sensitivity of human tumours to radiation, as well as conventional and experimental chemotherapeutic drugs, with regard to the role of growth factor-, DNA-repair-, and apoptotic- signalling.

    He and his group aim to develop new oncological treatments in the form of novel drug candidates and precision radiotherapy, with a personalized cancer medicine approach. The general interest of the research group is the development of novel treatments (both drugs and radiotherapy), mainly focused on lung cancer and furthermore breast, renal, and cervical cancer, multiple myeloma, and acute myeloid leukemia. From all types of malignancies, lung cancer is the leading cause of cancer-related mortality. Each year approximately 1.4 million people die worldwide because of lung cancer. Possibilities to increase survival of lung cancer patients are rapidly emerging. Early stages of lung cancer in the form of a localized intra-thoracic tumor or a tumor with a limited number of metastases may now be attacked with curative intent. However, lung cancer is often detected only at a late stage. Moreover, after an initial response to treatment, therapy-resistant clones inevitably start growing resulting in rapid disease progression. New knowledge of mutations specifically related to a certain type of cancer, identification of biomarkers to predict therapy response, and understanding of the molecular mechanisms of action of novel drugs opens up for personalization of treatment.

    A number of novel drug candidates, among which some are reacting with tumor DNA and/or directed to interfering with DNA repair, are being developed in the group's laboratory through a full preclinical test system preceding clinical trials. This includes analysis of biochemical mechanisms of action of these drugs and identification of corresponding putative biomarkers to create precision in selecting patients with sensitive tumors for a specific treatment, while patients with resistant disease can be deselected from unnecessary treatment causing only side effects. Part of the research is discovery, using a systems biology approach including genomic and proteomic methodologies, focusing on cell signaling pathways and DNA damage/repair. The research comprises of work on tumor cells lines, primary tumor material from the Karolinska Biobank and in vivo experiments to determine proof-of-principal and pharmacological parameters. The group has brought one compound Melflufen, which is a conjugate of a peptide and a DNA-alkylator, to a phase II clinical trial with multiple myeloma patients.

    In parallel, the group runs clinical trials on lung cancer at the Karolinska university hospital, in collaboration with pharmaceutical partners. A clinical trial program on precision-based hypofractionated stereotactic body radiotherapy (SBRT) is ongoing and rapidly being further developed. Most of these clinical trials are performed in conjunction with the Nordic SBRT study group, which is chaired by Prof. Lewensohn. SBRT seems promising in treatment of inoperable tumors, to improve survival of lung cancer patients. In several clinical trials, drug and radiotherapy are also combined as a novel strategy to cure patients with both early localized and early metastasized disease.

    Furthermore, the group has a leading role in the EurocanPlatform, an EU-funded project to bring together 28 European cancer institutions and organizations, with the aim to improve outcomes for cancer patients and reduce mortality. Within the Karolinska Institute, and Karolinska university hospital, Rolf Lewensohn is the primary initiator of the development of a personalized cancer medicine program. The ultimate goal of this program is to individualize therapy at all stages of disease by quickly and efficiently translating the latest scientific advances into concrete improvements of the care for cancer patients.

Articles

  • Journal article: TRANSLATIONAL LUNG CANCER RESEARCH. 2024;13(11):0
    Kamali C; Tsakonas G; Hydbring P; Jatta K; Berglund A; Viktorsson K; Lewensohn R; De Petris L; Ekman S
  • Journal article: CLINICAL AND TRANSLATIONAL SCIENCE. 2024;17(8):e13909
    Marzano L; Darwich AS; Dan A; Tendler S; Lewensohn R; De Petris L; Raghothama J; Meijer S
  • Journal article: ACS SENSORS. 2024;9(6):2935-2945
    Gevari MT; Sahu SS; Stridfeldt F; Haag P; De Petris L; Viktorsson K; Lewensohn R; Gori A; Cretich M; Dev A
  • Journal article: ESMO OPEN. 2024;9:102781
    Marzano L; Dan A; Tendler S; Darwich AS; de Petris L; Lewensohn R; Raghothama J; Meijer S
  • Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930
    Backlund E; Grozman V; Brage SE; Lewensohn R; Lindberg K; Helgadottir H
  • Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2023;117(5):1222-1231
    Lindberg S; Grozman V; Karlsson K; Onjukka E; Lindback E; Al Jirf K; Lax I; Wersall P; Persson GF; Josipovic M; Khalil AA; Moller DS; Hoffmann L; Knap MM; Nyman J; Drugge N; Bergstrom P; Olofsson J; Rogg LV; Hagen RK; Froland A-S; Ramberg C; Kristiansen C; Jeppesen SS; Nielsen TB; Loden B; Rosenbrand H-O; Engelholm S; Haraldsson A; Billiet C; Lewensohn R; Lindberg K
  • Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s353
    Kamali C; De Petris L; Jatta K; Viktorsson K; Lewensohn R; Ekman S; Hydbring P
  • Journal article: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s697
    Marzano L; Dan A; Tendler S; Darwich AS; Raghothama J; De Petris L; Lewensohn R; Meijer S
  • Journal article: JOURNAL OF GLOBAL ONCOLOGY. 2023;9(Supplement_1):113
    Marzano L; Darwich AS; Dan A; Tendler S; Raghotama J; Lewensohn R; De Petris L; Meijer S
  • Article: LUNG CANCER. 2023;182:107292
    Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
  • Article: CYTOPATHOLOGY. 2023;34(4):286-294
    Robeck P; Franzen B; Cantera-Ahlman R; Dragomir A; Auer G; Jorulf H; Jacobsson SP; Viktorsson K; Lewensohn R; Haggman M; Ladjevardi S
  • Article: TALANTA. 2023;259:124553
    Stridfeldt F; Cavallaro S; Haag P; Lewensohn R; Linnros J; Viktorsson K; Dev A
  • Article: CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(6):955-965
    Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
  • Article: STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS. 2023;302:18-22
    Marzano L; Meijer S; Dan A; Tendler S; De Petris L; Lewensohn R; Raghothama J; Darwich AS
  • Article: BIOSENSORS AND BIOELECTRONICS. 2023;227:115142
    Sahu SS; Gevari MT; Nagy A; Gestin M; Haag P; Lewensohn R; Viktorsson K; Karlstrom AE; Dev A
  • Journal article: RADIOTHERAPY AND ONCOLOGY. 2023;181:109492
    Cooke SA; de Ruysscher D; Reymen B; Lambrecht M; Persson GF; Faivre-Finn C; Dieleman EMT; Lewensohn R; Diessen JNAV; Sikorska K; Lalezari F; Vogel W; van Elmpt W; Damen EMF; Sonke J-J; Belderbos JSA
  • Article: CELL DEATH DISCOVERY. 2022;8(1):464
    Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Lain S
  • Article: JOURNAL OF EXTRACELLULAR VESICLES. 2022;11(11):e12277
    Banijamali M; Hojer P; Nagy A; Haag P; Paz Gomero E; Stiller C; Kaminskyy VO; Ekman S; Lewensohn R; Karlstrom AE; Viktorsson K; Ahmadian A
  • Article: MOLECULAR ONCOLOGY. 2022;16(20):3620-3641
    Viktorsson K; Haag P; Shah C-H; Franzen B; Arapi V; Holmsten K; Sandstrom P; Lewensohn R; Ullen A
  • Article: TRANSLATIONAL LUNG CANCER RESEARCH. 2022;11(10):2064-2078
    Alexeyenko A; Brustugun OT; Eide IJZ; Gencheva R; Kosibaty Z; Lai Y; de Petris L; Tsakonas G; Grundberg O; Franzen B; Viktorsson K; Lewensohn R; Hydbring P; Ekman S
  • Show more

All other publications

  • Review: MOLECULAR ONCOLOGY. 2024;18(11):2612-2628
    Franzen B; Auer G; Lewensohn R
  • Preprint: MEDRXIV. 2024
    Marzano L; Darwich AS; Dan A; Tendler S; Lewensohn R; De Petris L; Raghothama J; Meijer S
  • Corrigendum: CELL DEATH DISCOVERY. 2022;8(1):472
    Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Lain S
  • Preprint: BIORXIV. 2022
    Stridfeldt F; Cavallaro S; H氓氓g P; Lewensohn R; Linnros J; Viktorsson K; Dev A
  • Preprint: RESEARCH SQUARE. 2022
    Lain S; Alkasalias T; Zhang J; Madapura H; Dalaroun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S
  • Preprint: BIORXIV. 2022
    Gevari MT; Sahu SS; Stridfeldt F; H氓氓g P; Viktorsson K; Lewensohn R; Gori A; Cretich M; Dev A
  • Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
    Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
  • Letter: JOURNAL OF THORACIC ONCOLOGY. 2021;16(10):e81-e82
    Lindberg K; Lax I; Karlsson K; Lewensohn R
  • Preprint: BIORXIV. 2021
    Simao FA; Hieta R; Pulman JA; Madonna G; Ascierto PA; Lewensohn R; Masucci GV
  • Preprint: BIORXIV. 2021
    Cavallaro S; H氓氓g P; Sahu S; Berisha L; Kaminsky V; Ekman S; Lewensohn R; Linnros J; Viktorsson K; Dev A
  • Preprint: BIORXIV. 2021
    Cavallaro S; H氓氓g P; Viktorsson K; Krozer A; Fogel K; Lewensohn R; Linnros J; Dev A
  • Letter: ACTA ONCOLOGICA. 2020;59(1):28-32
    Ramqvist T; Ortiz-Villalon C; Branden E; Koyi H; de Petris L; Wagenius G; Brodin O; Reutersward C; Dalianis T; Jonsson M; Staaf J; Lewensohn R; Planck M
  • Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2020;18
    Mallardo D; Alexeyenko A; Capone M; Madonna G; Ong S; Warren S; Viktorsson K; Franzen B; Tuffanelli M; Curvietto M; Vanella V; Festino L; Vitale M; Scognamiglio G; Beechem J; Botti G; Cesano A; Lewensohn R; Masucci GV; Ascierto PA
  • Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S814
    Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
  • Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S842
    Ekman S; Varrone A; Jucaite A; Vishwanathan K; Brown A; Cselenyi Z; Martin H; Lewensohn R; Schou M; Laus G; Van Der Aart J; Johnstrom P; Singh N; Farde L
  • Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S784
    Ramqvist T; Ortiz-Villalon C; Branden E; Koyi H; De Petris L; Wagenius G; Brodin O; Reutersward C; Dalianis T; Jonsson M; Staaf J; Lewensohn R; Planck M
  • Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2019;14(10):S568-S569
    Salomonsson A; Jonsson M; Reutersward C; Behndig A; Bergman B; Botling J; Branden E; Brunnstrom H; De Petris L; Hussein A; Johansson M; Koyi H; Lundstrom KL; Lewensohn R; Monsef N; Ortiz-Villalon C; Patthey A; Vikstrom A; Wagenius G; Staaf J; Planck M
  • Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
    Madonna G; Capone M; Tuffanelli M; Curvietto M; Paone M; Esposito A; Sorrentino A; Palla M; Scarpato L; Mallardo D; Simeone E; Grimaldi A; Viktorsson K; Villabona L; Lewensohn R; Masucci G; Ascierto PA
  • Published conference paper: RADIATION PROTECTION DOSIMETRY. 2018;182(1):80-84
    Stenke L; Lindberg K; Lindberg ML; Lewensohn R; Valentin J; Powles R; Dainiak N
  • Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2018;13(10):S976
    Tendler S; Grozman V; Lewensohn R; Tsakonas G; Viktorsson K; De Petris L
  • Show more

Grants

  • Swedish Cancer Society
    1 January 2022
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Development of new curative treatment for lung cancer using precision radiation therapy alone and combined with targeting drugs or immunotherapy.
    Swedish Cancer Society
    1 January 2018
  • Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
    Swedish Cancer Society
    1 January 2017
  • VINNOVA
    11 April 2016 - 19 January 2017
  • Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
    Swedish Cancer Society
    1 January 2016
  • National Workshop on 鈥漃ersonalized Cancer Medicine鈥 (PCM)
    Swedish Foundation for Strategic Research
    10 August 2015 - 30 June 2016
  • Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
    Swedish Cancer Society
    1 January 2015
  • Molecular and clinical studies of lung cancer with the goal of creating improved and individualized treatment.
    Swedish Cancer Society
    1 January 2014
  • Swedish Research Council
    1 January 2010 - 31 December 2012

Employments

  • Professor, Senior, Department of Oncology-Pathology, 探花精选, 2025-2025
  • Professor, Department of Oncology-Pathology, 探花精选, 2020-2024

Degrees and Education

  • Docent, 探花精选, 1982

News from KI

Events from KI